Home » Stocks » MYL

Mylan N.V. (MYL)

Nov 17, 2020 - MYL merged into VTRS
Stock Price: $15.86 USD 0.00 (0.00%)
Updated Nov 16, 2021 4:00 PM EST
Market Cap 8.59B
Revenue (ttm) 11.51B
Net Income (ttm) 266.40M
Shares Out 516.90M
EPS (ttm) 0.52
PE Ratio 30.74
Forward PE 3.32
Dividend n/a
Dividend Yield n/a
Trading Day Nov 16, 2021
Last Price $15.86
Previous Close $15.86
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 15.34 - 16.15
Day's Volume 0
52-Week Range 12.75 - 23.11

News

Hide News
The Motley Fool - 3 months ago

The two pharma stocks offer investors the upside of a coronavirus vaccine with the peace of mind of century-old businesses.

Other stocks mentioned: PFE
Zacks Investment Research - 3 months ago

Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.

Zacks Investment Research - 3 months ago

Mylan (MYL) delivered earnings and revenue surprises of 14.78% and -0.24%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 3 months ago

There really isn't a downside to this deal.

Other stocks mentioned: PFE
Zacks Investment Research - 3 months ago

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.

Zacks Investment Research - 3 months ago

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PRNewsWire - 3 months ago

HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski, CFA, has joined the company as Head of Capital Markets, in a...

The Motley Fool - 4 months ago

The Federal Trade Commission has signed off on the deal.

Other stocks mentioned: PFE
Business Wire - 4 months ago

HERTFORDSHIRE, England & PITTSBURGH & NEW YORK--(BUSINESS WIRE)--Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepte...

Other stocks mentioned: PFE
Zacks Investment Research - 4 months ago

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GuruFocus - 4 months ago

To enhance the effectiveness of screening for value stocks, one method is to consider stocks whose "Graham blended multiplier" is less than 22.5. Developed by Benjamin Graham, the father of va...

Other stocks mentioned: LNC, RE
Insider Monkey - 4 months ago

In this article you are going to find out whether hedge funds think Mylan N.V. (NASDAQ:MYL) is a good investment right now. We like to check what the smart money thinks first before doing exte...

Forbes - 4 months ago

Going by the historical performance, we believe that the stock price of Mylan, a pharmaceutical company best known for its generic drugs, could offer an upside of over 45% from the current lev...

CNBC - 4 months ago

Two traders sift through a group of stocks "on sale" to find bargain buys in the market.

Other stocks mentioned: CVS, HPE, INTC, KR, LEN, LEN.B, T, TAP, TAP.A, TPR, TSN
Zacks Investment Research - 5 months ago

The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

Other stocks mentioned: PFE
PRNewsWire - 5 months ago

HERTFORDSHIRE, England and PITTSBURGH, Sept. 15, 2020 /PRNewswire/ -- Mylan N.V.

Zacks Investment Research - 5 months ago

Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.

PRNewsWire - 5 months ago

HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.

PRNewsWire - 5 months ago

HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.

Market Watch - 5 months ago

Mylan N.V. MYL, +2.26% said Tuesday it will pay EUR641.9 million ($756.8 million) for Aspen Pharmacare Holdings Ltd.

PRNewsWire - 5 months ago

HERTFORDSHIRE, England, and PITTSBURGH, Sept. 8, 2020 /PRNewswire/ -- Mylan N.V.

Zacks Investment Research - 5 months ago

Mylan (MYL) reported earnings 30 days ago. What's next for the stock?

24/7 Wall Street - 5 months ago

It might seem odd on Main Street that the S&P 500 has managed to recapture all its losses after the panic selling seen in February and March.

Other stocks mentioned: EPD, MU, NWL, OMC, RL, SO, T, WBA, WFC, XOM
PRNewsWire - 6 months ago

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Aug. 31, 2020 /PRNewswire/ -- Mylan N.V.

PRNewsWire - 6 months ago

HERTFORDSHIRE, England and PITTSBURGH, Aug. 28, 2020 /PRNewswire/ -- Mylan N.V.

Newsfile Corp - 6 months ago

Los Angeles, California--(Newsfile Corp. - August 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan ...

Newsfile Corp - 6 months ago

Los Angeles, California--(Newsfile Corp. - August 24, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan ...

Newsfile Corp - 6 months ago

Los Angeles, California--(Newsfile Corp. - August 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

Newsfile Corp - 6 months ago

Los Angeles, California--(Newsfile Corp. - August 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

Newsfile Corp - 6 months ago

Los Angeles, California--(Newsfile Corp. - August 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V.

PRNewsWire - 6 months ago

HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 /PRNewswire/ -- Mylan N.V.

PRNewsWire - 6 months ago

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V.

Seeking Alpha - 6 months ago

Goodwill and intangibles form $20.48 billion of Mylan’s $30.16 billion balance sheet. The company owes about $12 billion in long-term debt.

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclus...

Seeking Alpha - 6 months ago

Mylan, Inc. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 6 months ago

Mylan N.V. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.

Seeking Alpha - 6 months ago

Generic Drugs And Tensions With China: The Case For Mylan

Zacks Investment Research - 6 months ago

Mylan (MYL) delivered earnings and revenue surprises of 16.84% and 1.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Market Watch - 6 months ago

Mylan N.V. MYL, +3.55% said Thursday it had net income of $39.4 million, or 8 cents a share, in the second quarter, after a loss of $168.5 million, or 33 cents a share, in the year-earlier per...

Reuters - 6 months ago

Mylan NV reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.

PRNewsWire - 6 months ago

HERTFORDSHIRE, England and PITTSBURGH, Aug. 6, 2020 /PRNewswire/ -- Mylan N.V.

Zacks Investment Research - 7 months ago

Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.

Zacks Investment Research - 7 months ago

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

PRNewsWire - 7 months ago

HERTFORDSHIRE, England and PITTSBURGH, July 22, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2020 financi...

PRNewsWire - 7 months ago

NEW YORK, July 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7,...

Zacks Investment Research - 7 months ago

Mylan's (MYL) biosimilars portfolio gets a boost with the FDA approval of Hulio, a biosimilar of Humira.

PRNewsWire - 7 months ago

HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug ...

PRNewsWire - 7 months ago

HERTFORDSHIRE, England and PITTSBURGH, July 7, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nati...

About MYL

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the... [Read more...]

Industry
Drug Manufacturers—Specialty & Generic
Founded
1961
CEO
Heather M. Bresch
Employees
35,000
Stock Exchange
NASDAQ
Ticker Symbol
MYL
Full Company Profile

Financial Performance

In 2019, Mylan's revenue was $11.50 billion, an increase of 0.58% compared to the previous year's $11.43 billion. Earnings were $16.80 million, a decrease of -95.23%.

Financial Statements